Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market, threatening the position of both LAMAs and LABA / inhaled corticosteroid (ICS) FDCs. Because of the progressive and irreversible nature of COPD, many patients eventually require more-aggressive treatment and are prescribed a combination of a LABA, a LAMA, and an ICS, providing a market opportunity for the triple-therapy combinations (i.e., Trelegy and Breztri). The launch and uptake of generic versions of blockbuster inhaled drugs (e.g., salmeterol / fluticasone, formoterol / budesonide, albuterol sulfate) increase the affordability of treatment, further changing prescribing patterns.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Geography: United States
Real world data: Longitudinal patient-level claims data analysis
Key drugs covered: Albuterol sulfate, Anoro, Trelegy, Breztri, Incruse, Stiolto, Lonhala, Spiriva, Yupelri, Bevespi, Advair
Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses